CDK5 in oncology: recent advances and future prospects

被引：33

作者：

Lenjisa, Jimma Likisa ^{[1
]}

Tadesse, Solomon ^{[1
]}

Khair, Nishat Zareen ^{[1
]}

Kumarasiri, Malika ^{[1
]}

Yu, Mingfeng ^{[1
]}

Albrecht, Hugo ^{[1
]}

Milne, Robert ^{[1
]}

Wang, Shudong ^{[1
]}

机构：

[1] Univ South Australia, Ctr Drug Discovery & Dev, Sansom Inst Hlth Res, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia

来源：

FUTURE MEDICINAL CHEMISTRY | 2017年 / 9卷 / 16期

关键词：

cancer; cancer hallmarks; CDK; CDK5; inhibitors; p25; p35; targeted cancer therapy; CYCLIN-DEPENDENT KINASE-5; LUNG-CANCER CELLS; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA; BIOLOGICAL EVALUATION; INHIBITOR DINACICLIB; POTENTIAL TREATMENT; REGULATORY PROTEIN; TUMOR ANGIOGENESIS; ANDROGEN RECEPTOR;

D O I：

10.4155/fmc-2017-0097

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Selective abrogation of cyclin-dependent kinases (CDK) activity is a highly promising strategy in cancer treatment. The atypical CDK, CDK5 has long been known for its role in neurodegenerative diseases, and is becoming an attractive drug target for cancer therapy. Myriads of recent studies have uncovered that aberrant expression of CDK5 contributes to the oncogenic initiation and progression of multiple solid and hematological malignancies. CDK5 is also implicated in the regulation of cancer stem cell biology. In this review, we present the current state of knowledge of CDK5 as a druggable target for cancer treatment. We also provide a detailed outlook of designing selective and potent inhibitors of this enzyme.

引用

页码：1939 / 1962

页数：24

共 50 条

[31] Phosphorylation of Cyclin-dependent Kinase 5 (Cdk5) at Tyr-15 Is Inhibited by Cdk5 Activators and Does Not Contribute to the Activation of Cdk5
Kobayashi, Hiroyuki
Saito, Taro
Sato, Ko
Furusawa, Kotaro
Hosokawa, Tomohisa
Tsutsumi, Koji
Asada, Akiko
Kamada, Shinji
Ohshima, Toshio
Hisanaga, Shin-ichi
JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (28) : 19627 - 19636
[32] Cdk5 in neuroskeletal dynamics
Smith, D
NEUROSIGNALS, 2003, 12 (4-5) : 239 - 251
[33] The structural perspective on CDK5
Mapelli, M
Musacchio, A
NEUROSIGNALS, 2003, 12 (4-5) : 164 - 172
[34] Cell death and Cdk5
Lin, L
Zakeri, Z
PROCEEDINGS OF THE 5TH MULTINATIONAL CONGRESS ON ELECTRON MICROSCOPY, 2001, : 107 - 110
[35] Three decades of Cdk5
Pao, Ping-Chieh
Tsai, Li-Huei
JOURNAL OF BIOMEDICAL SCIENCE, 2021, 28 (01)
[36] Cdk5, the multifunctional surveyor
Lalioti, Vassiliki
Pulido, Diego
Sandoval, Ignacio V.
CELL CYCLE, 2010, 9 (02) : 284 - 311
[37] Cdk5 sinks into ALS
Patzke, H
Tsai, LH
TRENDS IN NEUROSCIENCES, 2002, 25 (01) : 8 - 10
[38] Kinase Cdk5 in tumors
Laurie A Dempsey
Nature Immunology, 2016, 17 (9) : 1015 - 1015
[39] Three decades of Cdk5
Ping-Chieh Pao
Li-Huei Tsai
Journal of Biomedical Science, 28
[40] Cdk5 variant 1 (cdk5-v1), but not full-length cdk5, is a centrosomal protein
Kim, Tom
Law, Vincent
Rosales, Jesusa L.
Lee, Ki-Young
CELL CYCLE, 2010, 9 (11) : 2251 - 2253

← 1 2 3 4 5 →